Kidney Week

Abstract: TH-PO1128

Implications of ADPKD Diagnosis at Young Age: A Post Hoc Analysis of the TEMPO 3:4 Trial

Session Information

• CKD: Clinical, Outcomes, Trials - I
  October 25, 2018 | Location: Exhibit Hall, San Diego Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: CKD (Non-Dialysis)

• 1902 CKD (Non-Dialysis): Clinical, Outcomes, and Trials

Authors

• Janssens, Peter, KULeuven, Leuven, Belgium

Peter Janssens,

• De Rechter, Stephanie Le, University Hospitals Leuven, Leuven, Belgium

Stephanie Le De Rechter,

• Bammens, Bert, University Hospitals Leuven, Leuven, Belgium

Bert Bammens,

• Grundmann, Franziska, University of Cologne, Cologne, Germany

Franziska Grundmann,

• Jouret, Francois, University of Liege Hospital (ULg CHU), Liege, Belgium

Francois Jouret,

• Liebau, Max, University Hospital Of Cologne; Children's Hospital, Koeln, Germany

Max Liebau,

• Mueller, Roman-Ulrich, Dept. 2 of Internal Medicine, University of Cologne, Koeln, Germany

Roman-Ulrich Mueller,

• Perrone, Ronald D., Tufts Medical Center, Boston, Massachusetts, United States

Ronald D. Perrone,

• Schaefer, Franz S., University of Heidelberg, Heidelberg, BW, Germany

Franz S. Schaefer,

• Pao, Christina, Otsuka Pharmaceutical Development and Commercialization, Princeton, New Jersey, United States

Christina Pao,

• Mekahli, Djalila, KULeuven, Leuven, Belgium

Djalila Mekahli,

Background

In ADPKD, there is currently limited information whether early diagnosis and management improve outcomes. We studied the implications of early diagnosis on outcome.

Methods

A post hoc analysis of TEMPO 3:4, a prospective, double-blind RCT in adults with ADPKD, with eCr ≥60 mL/min and TKV ≥750 mL. Comparison between patients diagnosed at age ≤18 years (childhood diagnosis [CD]) and >18 years (adult diagnosis [AD]).

Results

Patients were classified as CD in 20%, AD in 76% (Table 1), and unknown age at diagnosis in 4% (not shown) of the cases. At time of TEMPO 3:4 inclusion, CD were younger and had better eGFR than AD (Table 1). There were no significant differences in TKV, hypertension or RAASi use. Rates of TKV growth and eGFR changes by age at diagnosis are shown in Table 2.

Conclusion

The characterization of CD patients in TEMPO 3:4 shows that these participants were more severely affected based on a larger age-adapted TKV. Despite this fact, yearly TKV increase and loss of eGFR in the placebo arm of the study showed a tendency (NS) to be milder in the CD cohort. These data suggest the need for further evaluation of early intervention in the treatment of ADPKD.

Funding

• Commercial Support –